Effect of nicotine mouth spray on urges to vape: A randomized, placebo‐controlled, pharmacodynamic clinical trial in exclusive e‐cigarette users

Tobias Danielsson,Hedvig Bennet,Bryan McColgan,Jianfeng Wang
DOI: https://doi.org/10.1111/add.16669
2024-09-25
Addiction
Abstract:Aims To determine whether nicotine mouth spray provides rapid and prolonged relief of urges to vape and measure the steady‐state plasma nicotine levels during vaping and ad libitum mouth spray usage in e‐cigarette users. Design Randomized, parallel group, double‐blind trial. Setting Single site at Hammersmith Medicines Research Ltd (HMR), London, UK. Participants 216 (25.9% females, average age 27.6 ± 7.63 [standard deviation, SD]) exclusive vapers who used their e‐cigarette within 30 minutes of waking up and had vaped about 2 years on average. Interventions Two sprays of 1 mg nicotine mouth spray (Nicorette QuickMist Freshmint, n = 109), or placebo (identical in appearance and presentation, n = 107). Measurements Urge to vape was rated on a 100 mm visual analogue scale before and repeatedly for 2 hours after administration. The primary outcome measured average change from baseline in urges to vape ratings during the first hour. Findings Nicotine mouth spray achieved statistically significantly greater reductions in urges to vape than placebo from the first assessment point at 30 seconds to 1 hour, when the estimated mean treatment difference was 11.90 mm (95% confidence interval [CI] = 6.86–16.95, P
psychiatry,substance abuse
What problem does this paper attempt to address?